查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1420963

局部性腎小球硬化症市場 - 全球產業分析、規模、佔有率、成長、趨勢和預測，2023-2031 年

Focal Segmental Glomerulosclerosis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 163 Pages | 商品交期: 2-10個工作天內

價格

局部節段性腎小球硬化症市場 - 報告範圍

TMR 關於全球局部節段性腎小球硬化症市場的報告研究了過去以及當前的成長趨勢和機會，以獲得2023 年至2031 年預測期內市場指標的寶貴見解。該報告提供了全球局部性性節段性腎絲球硬化症的收入2017-2031年期間的市場，考慮2023年為基準年，2031年為預測年。報告中也提供了2023年至2031年全球局部節段性腎絲球硬化症市場的年複合成長率（CAGR %）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解局部節段性腎小球硬化症市場。

市場概況
2023年市場價值 5.385 億美元
2031 年市場價值 9.562 億美元
CAGR 6.5%

該報告深入研究了全球局部節段性腎小球硬化症市場的競爭格局。全球局部節段性腎小球硬化症市場的主要參與者已經確定，並且每一位參與者都已根據各種屬性進行了分析。公司概述、財務狀況、最新發展和 SWOT 是本報告中介紹的全球局部節段性腎小球硬化症市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概述

  • 介紹
  • 概述
  • 市場動態
  • 2017-2031年全球市場分析與預測

第 5 章：關鍵見解

  • 管道分析
  • 主要疾病類型/品牌分析
  • 主要併購
  • COVID-19 大流行對該行業的影響

第 6 章：全球市場分析與預測：依疾病類型

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依疾病類型，2017-2031
    • 基本的
    • 中學
  • 市場吸引力分析：按疾病類型

第 7 章：全球市場分析與預測：按疾病管理

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依疾病管理，2017-2031
    • 診斷
      • 腎臟活體組織切片
      • 肌酸酐測試
      • 其他
    • 治療
      • 藥物治療
      • 透析
      • 腎臟移植
  • 市場吸引力分析：按疾病管理

第 8 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2017-2031
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第 9 章：北美市場分析與預測

第 10 章：歐洲市場分析與預測

第 11 章：亞太市場分析與預測

第 12 章：拉丁美洲市場分析與預測

第 13 章：中東和非洲市場分析與預測

第 14 章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2022 年）
  • 公司簡介
    • Variant Pharmaceuticals, Inc.
    • ChemoCentryx, Inc.
    • Travere Therapeutics
    • AbbVie, Inc.
    • Novartis AG
    • Pfizer, Inc.
    • AstraZeneca plc.
    • Sanofi SA
    • GlaxoSmithKline plc.
    • Teva Pharmaceutical Industries Ltd.
Product Code: TMRGL31505

Focal Segmental Glomerulosclerosis Market - Scope of Report

TMR's report on the global focal segmental glomerulosclerosis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global focal segmental glomerulosclerosis market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global focal segmental glomerulosclerosis market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the focal segmental glomerulosclerosis market.

Market Snapshot
Market Value in 2023US$ 538.5 Mn
Market Value in 2031US$ 956.2 Mn
CAGR6.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global focal segmental glomerulosclerosis market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global focal segmental glomerulosclerosis market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global focal segmental glomerulosclerosis market.

The report delves into the competitive landscape of the global focal segmental glomerulosclerosis market. Key players operating in the global focal segmental glomerulosclerosis market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global focal segmental glomerulosclerosis market profiled in this report.

Key Questions Answered in Global focal segmental glomerulosclerosis Market Report:

  • What is the sales/revenue generated by focal segmental glomerulosclerosis across all regions during the forecast period?
  • What are the opportunities in the global focal segmental glomerulosclerosis market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Focal Segmental Glomerulosclerosis Market - Research Objectives and Research Approach

The comprehensive report on the global focal segmental glomerulosclerosis market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global focal segmental glomerulosclerosis market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global focal segmental glomerulosclerosis market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Focal Segmental Glomerulosclerosis Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Disease Type Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Disease Type/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Disease Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Disease Type, 2017-2031
    • 6.3.1. Primary Focal Segmental Glomerulosclerosis
    • 6.3.2. Secondary Focal Segmental Glomerulosclerosis
  • 6.4. Market Attractiveness Analysis, by Disease Type

7. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Disease Management

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Management, 2017-2031
    • 7.3.1. Diagnosis
      • 7.3.1.1. Kidney Biopsy
      • 7.3.1.2. Creatinine Test
      • 7.3.1.3. Others
    • 7.3.2. Treatment
      • 7.3.2.1. Drug Therapy
      • 7.3.2.2. Dialysis
      • 7.3.2.3. Kidney Transplant
  • 7.4. Market Attractiveness Analysis, by Disease Management

8. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2017-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America Focal Segmental Glomerulosclerosis Market Analysis and Forecast

  • 9.1. Introduction
  • 9.2. Key Findings
  • 9.3. Market Value Forecast, by Disease Type, 2017-2031
    • 9.3.1. Primary Focal Segmental Glomerulosclerosis
    • 9.3.2. Secondary Focal Segmental Glomerulosclerosis
  • 9.4. Market Value Forecast, by Disease Management, 2017-2031
    • 9.4.1. Diagnosis
      • 9.4.1.1. Kidney Biopsy
      • 9.4.1.2. Creatinine Test
      • 9.4.1.3. Others
    • 9.4.2. Treatment
      • 9.4.2.1. Drug Therapy
      • 9.4.2.2. Dialysis
      • 9.4.2.3. Kidney Transplant
  • 9.5. Market Value Forecast, by Country, 2017-2031
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. By Disease Type
    • 9.6.2. By Disease Management
    • 9.6.3. By Country

10. Europe Focal Segmental Glomerulosclerosis Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Disease Type, 2017-2031
    • 10.3.1. Primary Focal Segmental Glomerulosclerosis
    • 10.3.2. Secondary Focal Segmental Glomerulosclerosis
  • 10.4. Market Value Forecast, by Disease Management, 2017-2031
    • 10.4.1. Diagnosis
      • 10.4.1.1. Kidney Biopsy
      • 10.4.1.2. Creatinine Test
      • 10.4.1.3. Others
    • 10.4.2. Treatment
      • 10.4.2.1. Drug Therapy
      • 10.4.2.2. Dialysis
      • 10.4.2.3. Kidney Transplant
  • 10.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.5.1. Germany
    • 10.5.2. U.K.
    • 10.5.3. France
    • 10.5.4. Italy
    • 10.5.5. Spain
    • 10.5.6. Rest of Europe
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Disease Type
    • 10.6.2. By Disease Management
    • 10.6.3. By Country/Sub-region

11. Asia Pacific Focal Segmental Glomerulosclerosis Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Disease Type, 2017-2031
    • 11.3.1. Primary Focal Segmental Glomerulosclerosis
    • 11.3.2. Secondary Focal Segmental Glomerulosclerosis
  • 11.4. Market Value Forecast, by Disease Management, 2017-2031
    • 11.4.1. Diagnosis
      • 11.4.1.1. Kidney Biopsy
      • 11.4.1.2. Creatinine Test
      • 11.4.1.3. Others
    • 11.4.2. Treatment
      • 11.4.2.1. Drug Therapy
      • 11.4.2.2. Dialysis
      • 11.4.2.3. Kidney Transplant
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. China
    • 11.5.2. Japan
    • 11.5.3. India
    • 11.5.4. Australia & New Zealand
    • 11.5.5. Rest of Asia Pacific
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Disease Type
    • 11.6.2. By Disease Management
    • 11.6.3. By Country/Sub-region

12. Latin America Focal Segmental Glomerulosclerosis Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Disease Type, 2017-2031
    • 12.3.1. Primary Focal Segmental Glomerulosclerosis
    • 12.3.2. Secondary Focal Segmental Glomerulosclerosis
  • 12.4. Market Value Forecast, by Disease Management, 2017-2031
    • 12.4.1. Diagnosis
      • 12.4.1.1. Kidney Biopsy
      • 12.4.1.2. Creatinine Test
      • 12.4.1.3. Others
    • 12.4.2. Treatment
      • 12.4.2.1. Drug Therapy
      • 12.4.2.2. Dialysis
      • 12.4.2.3. Kidney Transplant
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Disease Type
    • 12.6.2. By Disease Management
    • 12.6.3. By Country/Sub-region

13. Middle East & Africa Focal Segmental Glomerulosclerosis Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Disease Type, 2017-2031
    • 13.3.1. Primary Focal Segmental Glomerulosclerosis
    • 13.3.2. Secondary Focal Segmental Glomerulosclerosis
  • 13.4. Market Value Forecast, by Disease Management, 2017-2031
    • 13.4.1. Diagnosis
      • 13.4.1.1. Kidney Biopsy
      • 13.4.1.2. Creatinine Test
      • 13.4.1.3. Others
    • 13.4.2. Treatment
      • 13.4.2.1. Drug Therapy
      • 13.4.2.2. Dialysis
      • 13.4.2.3. Kidney Transplant
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. GCC Countries
    • 13.5.2. South Africa
    • 13.5.3. Rest of Middle East & Africa
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Disease Type
    • 13.6.2. By Disease Management
    • 13.6.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2022)
  • 14.3. Company Profiles
    • 14.3.1. Variant Pharmaceuticals, Inc.
      • 14.3.1.1. Company Overview
      • 14.3.1.2. Disease Type Portfolio
      • 14.3.1.3. SWOT Analysis
      • 14.3.1.4. Financial Overview
      • 14.3.1.5. Strategic Overview
    • 14.3.2. ChemoCentryx, Inc.
      • 14.3.2.1. Company Overview
      • 14.3.2.2. Disease Type Portfolio
      • 14.3.2.3. SWOT Analysis
      • 14.3.2.4. Financial Overview
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Travere Therapeutics
      • 14.3.3.1. Company Overview
      • 14.3.3.2. Disease Type Portfolio
      • 14.3.3.3. SWOT Analysis
      • 14.3.3.4. Financial Overview
      • 14.3.3.5. Strategic Overview
    • 14.3.4. AbbVie, Inc.
      • 14.3.4.1. Company Overview
      • 14.3.4.2. Disease Type Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Financial Overview
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Novartis AG
      • 14.3.5.1. Company Overview
      • 14.3.5.2. Disease Type Portfolio
      • 14.3.5.3. SWOT Analysis
      • 14.3.5.4. Financial Overview
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Pfizer, Inc.
      • 14.3.6.1. Company Overview
      • 14.3.6.2. Disease Type Portfolio
      • 14.3.6.3. SWOT Analysis
      • 14.3.6.4. Financial Overview
      • 14.3.6.5. Strategic Overview
    • 14.3.7. AstraZeneca plc.
      • 14.3.7.1. Company Overview
      • 14.3.7.2. Disease Type Portfolio
      • 14.3.7.3. SWOT Analysis
      • 14.3.7.4. Financial Overview
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Sanofi S.A.
      • 14.3.8.1. Company Overview
      • 14.3.8.2. Disease Type Portfolio
      • 14.3.8.3. SWOT Analysis
      • 14.3.8.4. Financial Overview
      • 14.3.8.5. Strategic Overview
    • 14.3.9. GlaxoSmithKline plc.
      • 14.3.9.1. Company Overview
      • 14.3.9.2. Disease Type Portfolio
      • 14.3.9.3. SWOT Analysis
      • 14.3.9.4. Financial Overview
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1. Company Overview
      • 14.3.10.2. Disease Type Portfolio
      • 14.3.10.3. SWOT Analysis
      • 14.3.10.4. Financial Overview
      • 14.3.10.5. Strategic Overview

List of Tables

  • Table 01: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 02: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017-2031
  • Table 03: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 04: North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 05: North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 06: North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017-2031
  • Table 07: Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 8: Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 9: Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017-2031
  • Table 10: Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 11: Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 12: Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017-2031
  • Table 13: Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 15: Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017-2031
  • Table 16: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 18: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017-2031

List of Figures

  • Figure 01: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
  • Figure 02: Global Focal Segmental Glomerulosclerosis Market Revenue (US$ Mn), by Disease Type, 2022
  • Figure 03: Global Focal Segmental Glomerulosclerosis Market Value Share, by Disease Type, 2022
  • Figure 04: Global Focal Segmental Glomerulosclerosis Market Revenue (US$ Mn), by Disease Management, 2022
  • Figure 05: Global Focal Segmental Glomerulosclerosis Market Value Share, by Disease Management, 2022
  • Figure 06: Global Focal Segmental Glomerulosclerosis Market Value Share, by Region, 2022
  • Figure 07: Global Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 08: Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031
  • Figure 09: Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023-2031
  • Figure 10: Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2023 and 2031
  • Figure 11: Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023-2031
  • Figure 12: Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 13: Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 14: North America Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 15: North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 16: North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 17: North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031
  • Figure 18: North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031
  • Figure 19: North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023-2031
  • Figure 20: North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023-2031
  • Figure 21: Europe Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 22: Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 23: Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 24: Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031
  • Figure 25: Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031
  • Figure 26: Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023-2031
  • Figure 27: Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023-2031
  • Figure 28: Asia Pacific Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 29: Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 30: Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 31: Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031
  • Figure 32: Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031
  • Figure 33: Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023-2031
  • Figure 34: Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023-2031
  • Figure 35: Latin America Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 36: Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 37: Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 38: Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031
  • Figure 39: Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031
  • Figure 40: Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023-2031
  • Figure 41: Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023-2031
  • Figure 42: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 43: Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 44: Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 45: Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031
  • Figure 46: Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031
  • Figure 47: Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023-2031
  • Figure 48: Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023-2031